Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-05-31
2005-05-31
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093600, C435S320100
Reexamination Certificate
active
06899871
ABSTRACT:
A recombinant replication competent retrovirus for gene deliver and gene therapy is provided. The recombinant retrovirus has a heterologous nucleic acid sequence, a sequence encoding a cell- or tissue-specific ligand or a sequence for transcriptional targeting, or a combination of both a cell- or tissue-specific ligand and a cell- or tissue-specific transcriptional targeting sequence.
REFERENCES:
patent: 6033902 (2000-03-01), Haseltine et al.
patent: WO 00/18240 (2000-04-01), None
Kmiec, American Scientist, 1999, vol. 87, pp. 240-247.*
Gura, Science, 1997, vol. 278, pp. 1041-1042.*
Paillard, Human Gene Therapy, 1998, vol. 9, pp. 767-770.*
Anderson, Nature, 1998, vol. 392, pp. 25-30.*
Fox, Nature Biotechnology, 2000, vol. 18, pp. 143-144.*
Marshall, Science, 2003, vol. 299, p. 320.*
Gomez-Navarro et al., European Journal of Cancer, 1999, vol. 35, No. 6, pp. 867-885.*
Mountain, TIBTECH, 2000, vol. 18, pp. 119-128.*
Orkin, et al. :Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, www.nih.gov Dec. 1995.*
Verma et al. :Gene Therapy—promises , problems and prospects, Nature vol. 389, Sep. 1997, p. 239-242.*
Miller, et al.: , Trageted vectors for gene therapy, The FASEB Journal, vol. 9, Feb. 1995, p. 190-199.*
Jolly, Douglas : Viral vector systems for gene therapy, Cancer Gene Therapy, vol. 1, 1994, p. 51-64.*
Fu et al., “Viral sequences enable efficient and tissue-specific expression of transgenes in Xenopus”, Nature Biotechnology, vol. 6, Mar. 1988.
Morgan et al., “Retroviral vectors containing putative internal ribosome entry sites: development of polycistronic gene transfer system and applications to human gene therapy”, Nucleic Acid Research, vol. 20. No. 6, pp. 1293-1299.
Fassati, A., et al., “Insertion of Two Independent Enhancers in the Long Terminal Repeat of a Self-Inactivating Vector Results in High-Titer Retroviral Vectors with Tissue-Specific Expression”,Human Gene Therapy, 9:2459-2468 (Nov. 20, 1998).
Anderson W. French
Kasahara Noriyuki
Logg Christopher
Guzo David
University of Southern California
LandOfFree
Gene delivery system and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene delivery system and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene delivery system and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3442486